CU20120159A7 - Procedimiento para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico - Google Patents

Procedimiento para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico

Info

Publication number
CU20120159A7
CU20120159A7 CU2012000159A CU20120159A CU20120159A7 CU 20120159 A7 CU20120159 A7 CU 20120159A7 CU 2012000159 A CU2012000159 A CU 2012000159A CU 20120159 A CU20120159 A CU 20120159A CU 20120159 A7 CU20120159 A7 CU 20120159A7
Authority
CU
Cuba
Prior art keywords
peptide
inhibitors
proteasoma
formulate
procedure
Prior art date
Application number
CU2012000159A
Other languages
English (en)
Inventor
Evan Lewis
Peter Showonek
Sean Dalziel
Mouhannad Jumma
Original Assignee
Onyx Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49549072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120159(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics filed Critical Onyx Therapeutics
Publication of CU20120159A7 publication Critical patent/CU20120159A7/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente divulgación proporciona procedimientos para formular composiciones que comprenden uno o más inhibidores del proteasoma peptídico y una ciclodextrina, en particular una ciclodextrina sustituida.Dichos procedimientos incrementan considerablemente la solubilidad y la estabilidad de estos inhibidores del proteasoma y facilitan tanto su fabricación como su administración.
CU2012000159A 2012-05-08 2012-11-12 Procedimiento para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico CU20120159A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644122P 2012-05-08 2012-05-08
PCT/US2012/055127 WO2013169282A1 (en) 2012-05-08 2012-09-13 Cylodextrin complexation methods for formulating peptide proteasome inhibitors

Publications (1)

Publication Number Publication Date
CU20120159A7 true CU20120159A7 (es) 2014-03-26

Family

ID=49549072

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000159A CU20120159A7 (es) 2012-05-08 2012-11-12 Procedimiento para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico

Country Status (22)

Country Link
US (2) US20130303465A1 (es)
JP (1) JP2015516416A (es)
KR (1) KR20150007361A (es)
CN (1) CN103781490A (es)
AR (2) AR087863A1 (es)
AU (1) AU2012238318B2 (es)
BR (1) BR112012028726B1 (es)
CA (1) CA2793894A1 (es)
CO (1) CO6571868A2 (es)
CR (1) CR20120485A (es)
CU (1) CU20120159A7 (es)
DO (1) DOP2012000252A (es)
EA (1) EA201201519A1 (es)
EC (1) ECSP12012167A (es)
MA (1) MA35238B1 (es)
MX (1) MX2012010891A (es)
MY (2) MY196510A (es)
PH (1) PH12012502259A1 (es)
SG (1) SG194417A1 (es)
TW (1) TWI603737B (es)
WO (1) WO2013169282A1 (es)
ZA (1) ZA201207384B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2013123254A1 (en) 2012-02-15 2013-08-22 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
MX364393B (es) 2012-05-08 2019-04-24 Onyx Therapeutics Inc Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
EP2970225B1 (en) 2013-03-14 2018-08-15 Onyx Therapeutics, Inc. Dipeptide and tripeptide epoxy ketone protease inhibitors
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
WO2015009888A2 (en) 2013-07-19 2015-01-22 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CN104945470B (zh) 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
CN103936828A (zh) * 2014-05-12 2014-07-23 苏州科耐尔医药科技有限公司 卡非佐米中间体及卡非佐米的制备方法
CN105919972A (zh) * 2015-12-18 2016-09-07 重庆两江药物研发中心有限公司 一种包载卡非佐米的纳米粒制剂及其制备方法
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
MY204928A (en) 2016-08-05 2024-09-23 Amgen Inc Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
WO2018183686A1 (en) * 2017-03-31 2018-10-04 Valent Biosciences Llc 1-aminocyclopropane-1-carboxylic acid polymorphs
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
JP2021503441A (ja) 2017-11-16 2021-02-12 アムジエン・インコーポレーテツド Ｐｅｇ化されたカルフィルゾミブ化合物の安定組成物
CN111683654A (zh) * 2017-11-30 2020-09-18 细胞凝胶制药有限责任公司 新型镇痛药物制剂及其用途
JP2023510258A (ja) * 2020-01-10 2023-03-13 アムジエン・インコーポレーテツド 安定なシクロデキストリン不含カルフィルゾミブ処方物
IL298857A (en) * 2020-06-19 2023-02-01 Amgen Inc Methods for measuring carfilzomib
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19
CN113406183B (zh) * 2021-06-29 2024-04-23 常州磐诺仪器有限公司 基于离子淌度质谱仪高效识别青霉胺手性对映体的方法
WO2025035020A2 (en) 2023-08-09 2025-02-13 Amgen Inc. Methods of using carfilzomib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063154A1 (en) * 2004-12-07 2006-06-15 Proteolix, Inc. Composition for proteasome inhibition
US8716322B2 (en) * 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
JP5734656B2 (ja) * 2007-10-04 2015-06-17 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製

Also Published As

Publication number Publication date
PH12012502259A1 (en) 2019-07-03
JP2015516416A (ja) 2015-06-11
MA35238B1 (fr) 2014-07-03
CN103781490A (zh) 2014-05-07
NZ602490A (en) 2016-03-31
TWI603737B (zh) 2017-11-01
ZA201207384B (en) 2018-12-19
BR112012028726A2 (pt) 2016-07-19
AU2012238318B2 (en) 2014-02-13
US20130303482A1 (en) 2013-11-14
SG194417A1 (en) 2013-12-30
CR20120485A (es) 2013-12-18
KR20150007361A (ko) 2015-01-21
MY165002A (en) 2018-02-28
DOP2012000252A (es) 2013-12-31
US20130303465A1 (en) 2013-11-14
MY196510A (en) 2023-04-18
ECSP12012167A (es) 2013-02-28
AR087863A1 (es) 2014-04-23
TW201345543A (zh) 2013-11-16
BR112012028726B1 (pt) 2021-07-13
CO6571868A2 (es) 2012-11-30
WO2013169282A1 (en) 2013-11-14
EA201201519A1 (ru) 2013-11-29
AR127861A2 (es) 2024-03-06
AU2012238318A1 (en) 2013-11-28
MX2012010891A (es) 2014-03-05
CA2793894A1 (en) 2013-11-08

Similar Documents

Publication Publication Date Title
CU20120159A7 (es) Procedimiento para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico
CL2017000969A1 (es) Composiciones del factor viii y métodos para hacerlas y usarlas (divisional solicitud no. 2166-2014)
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
PL3003330T4 (pl) Terapia przywracająca mikrobiota (MRT), kompozycje i sposoby wytwarzania
GT201500051A (es) Inhibidores de glucosilceramida sintasa
MX2015010312A (es) Metodos para tratamiento del melanoma.
BR112016012146A8 (pt) derivados de aminopiridina como inibidores de quinase da família tam
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
TR201816379T4 (tr) DNA-PK inhibitörleri.
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CR20150250A (es) Nuevos derivados de piridina
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
CO7151512A2 (es) Inhibidores del nampt
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
EP4410374A3 (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
MX358132B (es) Solucion de trombina y metodos de uso de esta.
GEP201706675B (en) Imidazo-triazine derivatives as pde10 inhibitors
UY34829A (es) Nueva dosificación y formulación
BR112014019220A8 (pt) Novos derivados de pirrolidina
UA119441C2 (uk) Посилювачі водорозчинності на основі глікогену
MX2015016603A (es) Composiciones de corticosteroides.
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen